Principal Healthcare Innovators Index ETF (BTEC)
| Assets | $106.82M |
| NAV | $47.47 |
| Expense Ratio | 0.42% |
| PE Ratio | 23.18 |
| Shares Out | 2.25M |
| Dividend (ttm) | $0.22 |
| Dividend Yield | 0.45% |
| Ex-Dividend Date | Dec 17, 2020 |
| 1-Year Return |
| Volume | 3,479 |
| Open | 48.20 |
| Previous Close | 47.98 |
| Day's Range | 48.20 - 49.02 |
| 52-Week Low | 44.30 |
| 52-Week High | 44.30 |
| Beta | 1.20 |
| Holdings | 339 |
| Inception Date | Aug 19, 2016 |
About BTEC
The investment seeks to provide investment results that closely correspond, before expenses, to the performance of the Nasdaq Healthcare Innovators Index (the index). Under normal circumstances, the fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies that compose the index at the time of purchase. The index uses a quantitative model designed to identify equity securities in the Nasdaq US Benchmark Index that are small and medium capitalization U.S. healthcare companies.
Top 10 Holdings
24.47% of assets| Name | Symbol | Weight |
|---|---|---|
| Centene | CNC | 3.97% |
| Seagen | SGEN | 3.23% |
| Alnylam Pharmaceuticals | ALNY | 2.91% |
| Insulet | PODD | 2.65% |
| BioMarin Pharmaceutical | BMRN | 2.08% |
| Teladoc Health | TDOC | 2.06% |
| Viatris | VTRS | 1.98% |
| Abiomed | ABMD | 1.90% |
| Exact Sciences | EXAS | 1.86% |
| Elanco Animal Health | ELAN | 1.83% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Oct 1, 2021 | $0.000 | Oct 6, 2021 |
| Jul 1, 2021 | $0.000 | Jul 7, 2021 |
| Apr 1, 2021 | $0.000 | Apr 7, 2021 |
| Dec 17, 2020 | $0.21542 | Dec 22, 2020 |
| Dec 15, 2017 | $0.05134 | Dec 20, 2017 |
News
Can Biotech ETFs Gain From Positive Booster Update?
In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.
Biotech ETFs to Benefit From Latest Booster Update
The U.S. government's plans to make COVID-19 vaccine booster shots available from next month will likely increase the profits of vaccine makers.
Delta Variant Surge Brings Biotech ETFs in Focus
The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.
Goldman Sachs Likes These Health Tech Stocks
Broadly speaking, the healthcare sector is generally viewed as defensive, but there growing pockets of disruption and innovation in the space, including health technology equities. For investors looking...
Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines
The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.
An ETF to Home In on Innovative Health Care Growth
An exchange traded fund that tracks healthcare and technology themes can help diversify and enhance investment portfolios. In the recent webcast, Investing for tomorrow, today: Exploring the future of h...
Investing for Tomorrow, Today: Exploring the Future of Health Care
In the upcoming webcast, Investing for tomorrow, today: Exploring the future of health care, Steve Jones, Client Portfolio Manager, Principal Global Systematic Solutions; Jeffrey Schwarte, Portfolio Man...
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Health Tech x Remote Work: Principal's BTEC ETF
The coronavirus pandemic altered the healthcare landscape and how and where people work. The Principal Healthcare Innovators Index ETF (BTEC) is an exchange traded fund at the epicenter of those themes.
AI Can Drive the Next Generation of Healthcare Innovation
When it comes to innovation, healthcare is a sector-level leader, especially when the Principal Healthcare Innovators Index ETF (BTEC) taps into that trend. BTEC seeks to provide investment results that...
Biotech ETFs Pop Amid Pending J&J Vaccine Approval
Biotech ETFs are climbing Wednesday as the Food and Drug Administration's staff endorsed Johnson & Johnson's coronavirus vaccine for emergency use, a key step in offering a third vaccination to the U.S....
Bank on BTEC in the Ever-Elusive Search for Healthcare Innovation
The Principal Healthcare Innovators Index ETF (BTEC) became quite the story among healthcare exchange traded funds last year. BTEC seeks to provide investment results that closely correspond, before exp...
Moderna Helps Biotech ETFs Mitigate Massive Losses as Stocks Tumble
While much of the stock market and associated index ETFs are bathed in red to start the new year, Moderna is rallying, as the biotech company is boosting its vaccine output to help the spiking infection...
Top-Performing Biotech ETFs Amid the COVID-19 Crisis
The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.
Principal on Trends in Portfolio Construction Amid 2020 Volatility
ETF Trends CEO Tom Lydon spoke with Ed Nini, Global Head of Product Strategy for Principal Global Investors, about the tumultuous year that has been 2020 and what kinds of strategies have been put into ...
The BTEC ETF: Access to Consistent Healthcare Innovation
Bolstered by positioning that includes exposure to companies fighting the coronavirus pandemic, the Principal Healthcare Innovators Index ETF (BTEC) is a pleasant surprise among healthcare exchange trad...
Principal's BTEC ETF Luring Investors Seeking Telemedicine Exposure
The Principal Healthcare Innovators Index ETF (BTEC) is often viewed as an exchange traded fund with access to biotechnology stocks and companies working on coronavirus vaccines. That's true, but the fu...
ETF Opportunities Abound in an Increasingly Monolithic Healthcare Industry
With progress being made on the coronavirus vaccine front, the Principal Healthcare Innovators Index ETF (BTEC) is an example of a healthcare exchange traded fund getting into its groove. Fortunately, t...
Best Biotech ETFs for Q1 2021
The best biotech ETFs for Q1 2021 are ARKG, BTEC, and IDNA.
The Intensifying Vaccine Race Spells Success for BTEC
The race to bringing a coronavirus vaccine to market is heating up. That spells opportunity for the Principal Healthcare Innovators Index ETF (BTEC).